603 related articles for article (PubMed ID: 31888969)
1. White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease.
Soldan A; Pettigrew C; Zhu Y; Wang MC; Moghekar A; Gottesman RF; Singh B; Martinez O; Fletcher E; DeCarli C; Albert M;
Neurology; 2020 Mar; 94(9):e950-e960. PubMed ID: 31888969
[TBL] [Abstract][Full Text] [Related]
2. CSF amyloid is a consistent predictor of white matter hyperintensities across the disease course from aging to Alzheimer's disease.
Walsh P; Sudre CH; Fiford CM; Ryan NS; Lashley T; Frost C; Barnes J;
Neurobiol Aging; 2020 Jul; 91():5-14. PubMed ID: 32305782
[TBL] [Abstract][Full Text] [Related]
3. White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
van Waalwijk van Doorn LJC; Ghafoorian M; van Leijsen EMC; Claassen JAHR; Arighi A; Bozzali M; Cannas J; Cavedo E; Eusebi P; Farotti L; Fenoglio C; Fortea J; Frisoni GB; Galimberti D; Greco V; Herukka SK; Liu Y; Lleó A; de Mendonça A; Nobili FM; Parnetti L; Picco A; Pikkarainen M; Salvadori N; Scarpini E; Soininen H; Tarducci R; Urbani A; Vilaplana E; Meulenbroek O; Platel B; Verbeek MM; Kuiperij HB
J Alzheimers Dis; 2021; 79(1):163-175. PubMed ID: 33252070
[TBL] [Abstract][Full Text] [Related]
4. Regional White Matter Hyperintensities and Alzheimer's Disease Biomarkers Among Older Adults with Normal Cognition and Mild Cognitive Impairment.
Newton P; Tchounguen J; Pettigrew C; Lim C; Lin Z; Lu H; Moghekar A; Albert M; Soldan A;
J Alzheimers Dis; 2023; 92(1):323-339. PubMed ID: 36744337
[TBL] [Abstract][Full Text] [Related]
5. White Matter Hyperintensities in Mild Cognitive Impairment and Lower Risk of Cognitive Decline.
Nolze-Charron G; Mouiha A; Duchesne S; Bocti C;
J Alzheimers Dis; 2015; 46(4):855-62. PubMed ID: 26402625
[TBL] [Abstract][Full Text] [Related]
6. Vascular and Alzheimer's disease markers independently predict brain atrophy rate in Alzheimer's Disease Neuroimaging Initiative controls.
Barnes J; Carmichael OT; Leung KK; Schwarz C; Ridgway GR; Bartlett JW; Malone IB; Schott JM; Rossor MN; Biessels GJ; DeCarli C; Fox NC;
Neurobiol Aging; 2013 Aug; 34(8):1996-2002. PubMed ID: 23522844
[TBL] [Abstract][Full Text] [Related]
7. White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network.
Lee S; Viqar F; Zimmerman ME; Narkhede A; Tosto G; Benzinger TL; Marcus DS; Fagan AM; Goate A; Fox NC; Cairns NJ; Holtzman DM; Buckles V; Ghetti B; McDade E; Martins RN; Saykin AJ; Masters CL; Ringman JM; Ryan NS; Förster S; Laske C; Schofield PR; Sperling RA; Salloway S; Correia S; Jack C; Weiner M; Bateman RJ; Morris JC; Mayeux R; Brickman AM;
Ann Neurol; 2016 Jun; 79(6):929-39. PubMed ID: 27016429
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal Relationships of White Matter Hyperintensities and Alzheimer Disease Biomarkers Across the Adult Life Span.
Luo J; Ma Y; Agboola FJ; Grant E; Morris JC; McDade E; Fagan AM; Benzinger TLS; Hassenstab J; Bateman RJ; Perrin RJ; Gordon BA; Goyal M; Strain JF; Yakushev I; Day GS; Xiong C;
Neurology; 2023 Jul; 101(2):e164-e177. PubMed ID: 37202169
[TBL] [Abstract][Full Text] [Related]
10. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.
Vemuri P; Wiste HJ; Weigand SD; Shaw LM; Trojanowski JQ; Weiner MW; Knopman DS; Petersen RC; Jack CR;
Neurology; 2009 Jul; 73(4):294-301. PubMed ID: 19636049
[TBL] [Abstract][Full Text] [Related]
11. Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease.
Pettigrew C; Soldan A; Sloane K; Cai Q; Wang J; Wang MC; Moghekar A; Miller MI; Albert M;
Neuroimage Clin; 2017; 16():439-446. PubMed ID: 28879085
[TBL] [Abstract][Full Text] [Related]
12. White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment.
Guzman VA; Carmichael OT; Schwarz C; Tosto G; Zimmerman ME; Brickman AM;
Alzheimers Dement; 2013 Oct; 9(5 Suppl):S124-31. PubMed ID: 23375566
[TBL] [Abstract][Full Text] [Related]
13. Association between brain amyloid deposition and longitudinal changes of white matter hyperintensities.
Cha WJ; Yi D; Ahn H; Byun MS; Chang YY; Choi JM; Kim K; Choi H; Jung G; Kang KM; Sohn CH; Lee YS; Kim YK; Lee DY
Alzheimers Res Ther; 2024 Mar; 16(1):50. PubMed ID: 38454444
[TBL] [Abstract][Full Text] [Related]
14. Racial Disparity in Cerebrospinal Fluid Amyloid and Tau Biomarkers and Associated Cutoffs for Mild Cognitive Impairment.
Garrett SL; McDaniel D; Obideen M; Trammell AR; Shaw LM; Goldstein FC; Hajjar I
JAMA Netw Open; 2019 Dec; 2(12):e1917363. PubMed ID: 31834392
[TBL] [Abstract][Full Text] [Related]
15. The effect of white matter hyperintensities on neurodegeneration in mild cognitive impairment.
Tosto G; Zimmerman ME; Hamilton JL; Carmichael OT; Brickman AM;
Alzheimers Dement; 2015 Dec; 11(12):1510-1519. PubMed ID: 26079417
[TBL] [Abstract][Full Text] [Related]
16. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO
J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid biomarkers of neurofibrillary tangles and synaptic dysfunction are associated with longitudinal decline in white matter connectivity: A multi-resolution graph analysis.
Kim WH; Racine AM; Adluru N; Hwang SJ; Blennow K; Zetterberg H; Carlsson CM; Asthana S; Koscik RL; Johnson SC; Bendlin BB; Singh V
Neuroimage Clin; 2019; 21():101586. PubMed ID: 30502079
[TBL] [Abstract][Full Text] [Related]
18. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
[TBL] [Abstract][Full Text] [Related]
19. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
20. CSF biomarker changes precede symptom onset of mild cognitive impairment.
Moghekar A; Li S; Lu Y; Li M; Wang MC; Albert M; O'Brien R;
Neurology; 2013 Nov; 81(20):1753-8. PubMed ID: 24132375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
